Epitalon

Epitalon, also spelled epithalon, is a four-link synthetic peptide with the sequence Ala-Glu-Asp-Gly. Researchers in St. Petersburg built it from the amino-acid makeup of epithalamin, an extract of cattle pineal glands [7]. It is sold as an anti-aging peptide on the claim that it switches on telomerase, the enzyme that rebuilds the protective caps at the ends of chromosomes.

The extract and the synthetic peptide are easy to confuse, and sellers often do. The best-known human results, lower death rates among elderly people followed for years, come from epithalamin. FDA treats the two as different substances [8]. For epitalon itself FDA found three small human studies, none designed to show a health benefit, and no clinical data on its safety [8].

On October 28, 2026 an interim HHS policy opened a narrow compounding route. State-licensed pharmacies and physicians may compound epitalon acetate as an injection given in intermittent courses, under conditions, without expecting enforcement action [9]. The policy does not approve it and does not touch the evidence.

The core finding is from cell culture. In 2003 the St. Petersburg group added the peptide to human fetal lung fibroblasts that do not normally make telomerase and reported that the cells began producing it and their telomeres lengthened [1]. A follow-up reported that treated cells went on dividing for ten passages beyond the point where untreated cells stopped [2].

In 2025 a lab at Brunel University London, outside that group, saw telomeres lengthen in normal human cell lines through telomerase. In breast cancer cell lines the telomeres also lengthened, through a separate mechanism called ALT [3]. That second result matters for safety as much as for efficacy, since unlimited cell division is a feature of cancer. FDA made the same point in its review: by activating telomerase the peptide could in principle raise cancer risk, and the animal studies were too limited to rule that out [8].

Animal work is mixed. In a 2003 study of 54 mice per group, monthly injections did not change average life span, total tumor rates or body weight. The longest-lived tenth of treated mice lived 13.3% longer than their counterparts, maximum life span was 12.3% longer, and leukemia was less common [4].

In people, the headline numbers are not about this peptide. A 2003 paper reported 1.6 to 1.8 times lower mortality over six to eight years in elderly patients given epithalamin [5], and a 12-year study reported 28% fewer deaths in the epithalamin group than in controls [6]. Both used the pineal extract. The three human studies of epitalon FDA identified covered gene expression and a melatonin marker in night-shift workers and an eye disease, retinitis pigmentosa, in small groups [8]. An orphan drug designation for retinitis pigmentosa was granted in 2010 and revoked in 2016 [8].

Almost all of the literature comes from one research group, and the only independent replication so far is in cell lines. Grade D. Our evidence review sets out each study, the source of the mortality figures and what FDA's 2026 review found.

No human dose has been established. The mouse study used about 30 to 40 mcg per kg for five days each month [4], and the human studies of the peptide itself were too small and too different in route to set a regimen. Vendor and forum dosing has no tested basis.

The HHS policy shapes how a compounded product may be given rather than how much. It covers only subcutaneous or intramuscular injection of epitalon acetate, dispensed in intermittent courses, as the sole active ingredient, on a prescription for one patient [9]. Capsules and oral sprays, which FDA found on sale, fall outside it [8].

There is too little data to describe the risks in people. FDA found no acute, repeat-dose or reproductive toxicity studies, its adverse-event searches returned no reports, and it concluded that no clinical data support the peptide's safety in humans [8]. HHS, explaining its policy, wrote that the few people given it under controlled conditions had no reported side effects, and that people take it in short courses rather than continuously [9]. Both statements rest on very few people.

The theoretical concern is cancer. A compound that lengthens telomeres, and did so in cancer cells in one lab, deserves long-term study before anyone takes it for years, and that study has not been done [3] [8]. Under the October 28, 2026 policy a covered pharmacy must source tested bulk peptide from an FDA-registered facility and tell FDA through MedWatch about serious harm, which at least starts a record [9]. HHS can withdraw the interim policy if a safety problem surfaces. Research-use-only vials come with none of those checks.